OSTX AMEX
OS Therapies Incorporated
1W: -1.8%
1M: -4.7%
3M: +1.2%
YTD: +21.6%
1Y: -18.5%
$1.62
+0.01 (+0.62%)
Weekly Expected Move ±7.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$73.8M
52W Range1.15-2.25
Volume231,498
Avg Volume635,461
Beta-0.68
Dividend—
Analyst Ratings
Company Info
CEOPaul A. Romness
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2024-08-01
Websiteostherapies.com
115 Pullman Crossing Road
Grasonville, MD 21638
US
Grasonville, MD 21638
US
410-297-7793
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Latest News
OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO
OS Therapies (NYSEAMERICAN:OSTX) Stock Price Down 2.5% – Time to Sell?
OS Therapies GAAP EPS of -$0.20 misses by $0.03
12 Health Care Stocks Moving In Thursday's After-Market Session
OS Therapies Incorporated (OSTX) Q1 2026 Earnings: EPS Misses Estimates as Operating Losses Widen - Performance Review - newsline.com
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| EAGLE CRAIG | 0 | — | 2026-07-01 | |
| McKean-Dieser Avril | A-Award | 50,000 | $1.34 | 2026-01-22 |
| Search Theodore F. | A-Award | 50,000 | $1.34 | 2026-01-22 |
| Ciccio John | A-Award | 50,000 | $1.34 | 2026-01-22 |
| Acevedo Christopher | A-Award | 100,000 | $1.34 | 2026-01-22 |